10 completed, 4 unknown, 3 recruiting, 3 terminated. 8 Phase 2, 5 Phase 3, 4 Phase 1, 3 Not applicable, 2 Phase 4.
Follow Chlorpheniramine: new trials by email Literature Review of Chlorpheniramine trials Research Report on Chlorpheniramine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate in Improving Symptoms of the Common Cold and Flu in Adults dipyrone monohydrate 1000 mg + chlorpheniramine maleate 4 mg + caffeine 60 mg, dipyrone monohydrate 500 mg + chlorpheniramine maleate 2 mg + caffeine 30 mg, Placebo - Common Cold/Flu, Nasal Congestion | Phase 3 | Recruiting | Brainfarma Industria Química e Farmacêutica S/A | 620 | 2026-05-08 | 2026-06-16 |
| Antihistamine for Prevention of HTR After Blood Primed CPB Antihestamine, Placebo - Blood Transfusion Associated Adverse Reactions | Phase 4 | Recruiting | Kasr El Aini Hospital | 40 | 2026-03-01 | 2026-04-21 |
| First-generation OTC Antihistamine Use and Voice Function: A Preliminary Study Chlor-Trimeton. - Voice Disorder Due to Iatrogenic Factor | Early Phase 1 | Completed | Auburn University | 8 | 2023-06-13 | 2024-04-24 |
| Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III Chlorpheniramine Maleate 0.4% Nasal Spray, Placebo - COVID-19, Symptoms and Signs | Phase 2 / Phase 3 | Completed | Dr. Ferrer BioPharma | 157 | 2022-07-27 | 2023-06-02 |
| Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I Chlorpheniramine Maleate 1% Nasal Spray, Placebo - COVID-19, Symptoms and Signs | Phase 2 / Phase 3 | Completed | Dr. Ferrer BioPharma | 101 | 2021-12-07 | 2023-03-23 |
| Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray - COVID-19, COVID-19 Pandemic | Unknown | Dr. Ferrer BioPharma | 1000 | 2021-08-26 | 2022-08-30 | |
| Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions. Placebo, Chlorpheniramine - Allergic Transfusion Reaction | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 6642 | 2021-01-01 | 2026-11-12 |
| Chlorpheniramine Maleate Nasal Spray for Chronic Rhinitis CPM, Placebo - Allergic Rhinitis, Nasal Congestion | Phase 2 / Phase 3 | Withdrawn | Larkin Community Hospital | 2019-07-30 | 2023-10-16 | |
| Non-interaction Study of Chlorthalidone and Losartan in Fixed Combination, in Healthy Subjects, Under Fasting Conditions Chlorthalidone (HIGROTON® 50), Losartan (COZZAR®), A1+ A2 Co-administration of Chlorthalidone and Losartan - Healthy | Phase 1 | Completed | Laboratorios Silanes S.A. de C.V. | 36 | 2019-05-01 | 2021-10-22 |
| Effect of the Antihistamine Injection to Prevent Paradoxical Reaction During Sedative Endoscopy Chlorpheniramine and midazolam, Midazolam - Endoscopy | Not applicable | Unknown | Seoul National University Hospital | 220 | 2019-05-01 | 2020-04-17 |
| Anti-histamines Promote Electroacupuncture Analgesia: Basic and Clinical Research electroacupuncture, antihistamine(low dose) chlorpheniramine (Dexchlorpheniramine maleate), antihistamine(high dose) chlorpheniramine (Dexchlorpheniramine maleate) - Pain | Not applicable | Completed | China Medical University Hospital | 40 | 2019-01-24 | 2020-01-09 |
| Effect of Anti-histamine in Prevention Systolic Hypotension After Protamine Chlorpheniramine and ranitidine, 0.9% Normal Saline - Protamine Adverse Reaction | Phase 4 | Completed | Mahidol University | 40 | 2018-09-05 | 2021-09-01 |
| Clinical Trial of the Safety and Efficacy of SP160412 in the Temporary Relief of Mild to Moderate Sunburn SP160412 Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg, 2 capsules Ibuprofen and 1 placebo, capsule Chlorpheniramine 4mg and 1 Placebo - Sunburn | Phase 2 | Terminated | Sephoris Pharmaceuticals LLC | 80 | 2018-01-15 | 2019-09-27 |
| Exploratory Study for Allergy Relief Onset Chlorpheniramine maleate (BAY X002134), Placebo - Rhinitis, Allergic | Phase 2 | Terminated | Bayer | 1 | 2016-05-07 | 2018-12-12 |
| A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection ARC-520, Placebo, entecavir - Hepatitis B, Chronic | Phase 2 | Terminated | Arrowhead Pharmaceuticals | 58 | 2014-03-01 | 2026-01-13 |
| StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study PSE 120 mg, CM 8 mg, Atr 0.36 mg, PSE 120 mg, CM 8 mg, Atr 0.24 mg, PSE 120 mg, CM 8 mg, Atr 0.12 mg - Rhinitis, Seasonal, Allergic | Phase 2 | Unknown | Magna Pharmaceuticals, Inc. | 125 | 2014-03-01 | 2014-05-30 |
| Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects Chlorphenamine and Ranitidine, Paracetamol - Poisoning | Not applicable | Completed | University of Edinburgh | 24 | 2011-01-03 | 2024-06-20 |
| Efficacy and Safety Assessment of an Anti-Cold Preparation in the Symptomatic Treatment of Common Cold and Flu-Like Syndrome Resfenol, Placebo, Co interventional acetaminophen - Common Cold, Flu-like Syndrome | Phase 3 | Unknown | Hospital de Clinicas de Porto Alegre | 146 | 2009-06-01 | 2009-07-16 |
| Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents Chlorpheniramine - Allergic Reactions | Phase 1 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 36 | 2008-12-21 | 2020-10-23 |
| Fed Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex® Pennkinetic® Extended Release Oral Suspension Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule, 5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension - Healthy | Phase 1 | Completed | Mallinckrodt | 43 | 2003-09-01 | 2016-10-19 |
Showing 20 of 21. Sign in to see all of them.
COVID-19 (3) · Common Cold (2) · Coronavirus Infections (2) · Nasal Obstruction (2) · Rhinitis, Allergic (2) · Signs and Symptoms (2) · Anaphylaxis (1) · Hepatitis (1) · Hepatitis B, Chronic (1) · Hypersensitivity (1) · Influenza, Human (1) · Pain (1) · Poisoning (1) · Rhinitis (1) · Rhinitis, Allergic, Seasonal (1)
Dr. Ferrer BioPharma (3) · Mallinckrodt (2) · Arrowhead Pharmaceuticals (1) · Auburn University (1) · Bayer (1) · Brainfarma Industria Química e Farmacêutica S/A (1) · China Medical University Hospital (1) · Hospital de Clinicas de Porto Alegre (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Kasr El Aini Hospital (1) · Laboratorios Silanes S.A. de C.V. (1) · Larkin Community Hospital (1) · Magna Pharmaceuticals, Inc. (1) · Mahidol University (1) · Seoul National University Hospital (1)
United States (5) · Brazil (2) · Honduras (2) · China (1) · Dominican Republic (1) · Egypt (1) · Hong Kong (1) · Mauritius (1) · Mexico (1) · South Korea (1) · Taiwan (1) · Thailand (1) · United Kingdom (1)
Herbert Neuman, MD (2) · Araceli G Medina Nolasco, M.D (1) · Bruce Given, MD (1) · Euan A Sandilands, MRCP BSc (1) · Gitanjali Petkar, M.D (1) · Liz J Medina Reyes, M.D (1) · Marcos A Sanchez-Gonzalez (1) · Mary J Sandage, PhD (1) · Sirilak Suksompong, MD (1) · Stephen J Pollard, MD (1) · Yi-Hung Chen, PhD (1)
PMID 16377322, PMID 24893689, PMID 28159539, PMID 29136286, PMID 29689257, PMID 33712437, PMID 36081814, PMID 36571171